Azora Therapeutics, Inc. (DE) (ADIL): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Azora Therapeutics, Inc. (DE) (ADIL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of New Directors On November 3, 2026, each of Aida Habtezion, M.D., Paul Hastings and Thomas Soloway were appoi
- Person
- Aida Habtezion, M.D.
- Title
- Class I director
- Action
- appointed
- Effective
- November 3, 2026
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The governance update and share conversion are primary disclosures that may influence investor perception of control and dilution.
Market read
Governance and equity structure changes are modest but could affect short‑term price dynamics.
What to watch
Potential future equity compensation for directors could further affect dilution.
Background
Azora Therapeutics filed an 8‑K detailing director appointments and conversion of preferred stock following its recent acquisition.
Ticker impact
SEC 8‑K reports appointment of three new directors and conversion of Series A preferred into common shares, changing board composition and share count.
likely modest pressure as market prices in the dilution and evaluates new directors' expertise
The filing is the first public disclosure of these changes; no immediate financial metrics are provided, so impact is limited to governance and equity structure.
Market effects
minor impact on biotech sector governance trends
none
low
Counterpoint
Board changes could signal strategic shift that may unlock value if new directors drive partnerships.
Key entities
- companyAzora Therapeutics, Inc.
Biopharma company filing the 8‑K.
- personAida Habtezion
New independent director, former Pfizer CMO.
- personPaul J. Hastings
New independent director, CEO of Nkarta.
- personThomas Soloway
New independent director, CEO of T‑knife Therapeutics.
